R377
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 93
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.350
- PANCREAS_BETA_CELLS+0.280
- PROTEIN_SECRETION+0.230
- UV_RESPONSE_DN+0.190
- KRAS_SIGNALING_UP+0.170
- P53_PATHWAY+0.140
- TNFA_SIGNALING_VIA_NFKB+0.140
- HYPOXIA+0.110
- ANGIOGENESIS+0.100
- INTERFERON_ALPHA_RESPONSE+0.070
Top 10 suppressed
- E2F_TARGETS-0.510
- G2M_CHECKPOINT-0.440
- CHOLESTEROL_HOMEOSTASIS-0.340
- MYC_TARGETS_V2-0.340
- NOTCH_SIGNALING-0.300
- MITOTIC_SPINDLE-0.290
- DNA_REPAIR-0.260
- PI3K_AKT_MTOR_SIGNALING-0.240
- SPERMATOGENESIS-0.240
- UV_RESPONSE_UP-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R347 | — | — | 0.843 |
| 2 | SRR10900594 | — | — | 0.758 |
| 3 | R352 | — | — | 0.729 |
| 4 | AUR-AER8-TTP1-A-1-0-R-A741-41 | — | D | 0.728 |
| 5 | 20020052.LumA | — | A | 0.715 |
| 6 | SRR10900003 | — | — | 0.710 |
| 7 | SRR8518163 | — | A | 0.704 |
| 8 | SRR8943020 | — | — | 0.700 |
| 9 | C3N-03038 | — | cohortA1 | 0.693 |
| 10 | TCGA-44-A47B-01A-11R-A24H-07 | — | cohortA1 | 0.693 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.140 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| HYPOXIA | 0.110 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |